Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Treatment of Post-Transplant Relapse and Persistent Disease in Patients With MDS, CMML and AML With Azacitidine

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT01083706
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:36:33.668319+00:00
Published At
2017-05-24T00:00:00+00:00
Record Updated At
2017-05-24
Results Posted At
2017-05-24
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Childhood Myelodysplastic Syndromes", "Chronic Myelomonocytic Leukemia", "Previously Treated Myelodysplastic Syndromes", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Childhood Acute Myeloid Leukemia", "Secondary Myelodysplastic Syndromes"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2017-05-24"
protocolSection.identificationModule.nctId
"NCT01083706"
protocolSection.identificationModule.officialTitle
"Treatment of Post-Transplant Relapse and Persistent Disease in Patients With MDS, CMML and AML With Azacitidine"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2017-05-24"

Study condition terms

  • Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities (protocolSection.conditionsModule.conditions)
  • Adult Acute Myeloid Leukemia With Del(5q) (protocolSection.conditionsModule.conditions)
  • Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) (protocolSection.conditionsModule.conditions)
  • Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) (protocolSection.conditionsModule.conditions)
  • Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) (protocolSection.conditionsModule.conditions)
  • Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) (protocolSection.conditionsModule.conditions)
  • Childhood Myelodysplastic Syndromes (protocolSection.conditionsModule.conditions)
  • Chronic Myelomonocytic Leukemia (protocolSection.conditionsModule.conditions)
  • Previously Treated Myelodysplastic Syndromes (protocolSection.conditionsModule.conditions)
  • Recurrent Adult Acute Myeloid Leukemia (protocolSection.conditionsModule.conditions)
  • Recurrent Childhood Acute Myeloid Leukemia (protocolSection.conditionsModule.conditions)
  • Secondary Myelodysplastic Syndromes (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.